dockets: FDA-2025-P-4151

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id title docket_type last_modified object_id
FDA-2025-P-4151 FDA Requests that FDA determine whether ReVia (naltrexone HCl) Tablets, 50 mg, approved under New Drug Application (NDA) number 018932, held by Teva Women’s Health, Inc., has been voluntarily withdrawn for reasons of safety or effectiveness Nonrulemaking 2026-04-21T12:49:27Z 0b000064b8fd6fe0

Links from other tables